Xilio Therapeutics, Inc.

Contributing Author

Recent Articles by Xilio Therapeutics, Inc.

Sep-09	Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead XLO GlobeNewswire
Aug-14	Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results XLO GlobeNewswire
Aug-01	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) XLO GlobeNewswire
Jul-02	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) XLO GlobeNewswire
Jun-10	Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors XLO GlobeNewswire
Jun-05	Xilio Therapeutics Announces Closing of $50.0 Million Public Offering XLO GlobeNewswire
Jun-03	Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) XLO GlobeNewswire
Jun-02	Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering XLO GlobeNewswire
Jun-02	Xilio Therapeutics Announces Proposed Public Offering XLO GlobeNewswire
May-31	Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer XLO GlobeNewswire
May-08	Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results XLO GlobeNewswire
May-02	Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) XLO GlobeNewswire